 |
|
|
| |
SOF/VEL/VOX for 8 or 12 Weeks Is Well Tolerated and Results in
High SVR12 Rates in Patients Receiving Opioid Substitution Therapy
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-22 Amsterdam Netherlands
Jason Grebely,1 Ira M. Jacobson,2 Zeid Kayali,3 Elizabeth C. Verna,4 Mitchell L.
Shiffman,5 Robert H. Hyland,6 Luisa M. Stamm,6
K.C. Huang,6 Diana M. Brainard,6 John G. McHutchison,6 Stanislas Pol,7 Raymond T. Chung,8 David E. Bernstein,9 Gregory Dore1
1The Kirby Institute, UNSW Australia, Sydney, New South Wales, Australia; 2Mount Sinai Beth Israel, New York, New York, USA; 3Inland Empire Liver Foundation, Rialto, California, USA; 4Columbia University, New York; 5Liver Institute of Virginia, Richmond, USA;
6Gilead Sciences, Inc., Foster City, California; 7Université Paris Descartes, Hopital Cochin, Paris, France; 8Massachusetts General Hospital, Boston, Massachusetts, USA; 9Hofstra Northwell School of Medicine at Hofstra University, Hempstead, New York
|
| |
|
|
|
|
|
